Risk assessment, diagnosis, and treatment of cancer treatment-related adrenal insufficiency

2022 ◽  
pp. 1-13
Author(s):  
Annabelle G Hayes ◽  
R. Louise Rushworth ◽  
David J Torpy
Keyword(s):  
Risk Assessment ◽  
Cancer Treatment ◽  
Adrenal Insufficiency ◽  
Diagnosis And Treatment

Recent Advances of Silver Nanoparticles in Cancer Diagnosis and Treatment

2020 ◽  
Vol 20 (11) ◽  
pp. 1276-1287 ◽  
Author(s):  
Tran Q. Huy ◽  
Pham T.M. Huyen ◽  
Anh-Tuan Le ◽  
Matteo Tonezzer
Keyword(s):  
Silver Nanoparticles ◽  
Cancer Treatment ◽  
Cancer Diagnosis ◽  
Essential Role ◽  
Review Paper ◽  
Diagnosis And Treatment ◽  
Antimicrobial Material ◽  
Pathogenic Agents ◽  
New Generation ◽  
Carrier Systems

Background: Silver nanoparticles (AgNPs) are well-known as a promising antimicrobial material; they have been widely used in many commercial products against pathogenic agents. Despite a growing concern regarding the cytotoxicity, AgNPs still have attracted considerable interest worldwide to develop a new generation of diagnostic tool and effective treatment solution for cancer cells. Objective: This paper aims to review the advances of AgNPs applied for cancer diagnosis and treatment. Methods: The database has been collected, screened and analysed through up-to-date scientific articles published from 2007 to May 2019 in peer-reviewed international journals. Results: The findings of the database have been analysed and divided into three parts of the text that deal with AgNPs in cancer diagnosis, their cytotoxicity, and the role as carrier systems for cancer treatment. Thanks to their optical properties, high conductivity and small size, AgNPs have been demonstrated to play an essential role in enhancing signals and sensitivity in various biosensing platforms. Furthermore, AgNPs also can be used directly or developed as a drug delivery system for cancer treatment. Conclusion: The review paper will help readers understand more clearly and systematically the role and advances of AgNPs in cancer diagnosis and treatment.

scholarly journals Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease

2008 ◽  
Vol 178 (5) ◽  
pp. 548-556 ◽  
Author(s):  
C. Patterson ◽  
J. W. Feightner ◽  
A. Garcia ◽  
G.-Y. R. Hsiung ◽  
C. MacKnight ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Primary Prevention ◽  
Alzheimer Disease ◽  
Diagnosis And Treatment

scholarly journals Ten-year experience of the Pirogov Center in the organization of oncological care in a multi-field hospital

2019 ◽  
Vol 24 (3) ◽  
pp. 115-123
Author(s):  
Yu. L. Shevchenko ◽  
O. E. Karpov ◽  
V. O. Sarzhevskiy ◽  
S. A. Fateev ◽  
P. S. Vetshev ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Medical Care ◽  
Cancer Patients ◽  
Multidisciplinary Approach ◽  
Diagnosis And Treatment ◽  
High Tech ◽  
Care Organization ◽  
Field Hospital ◽  
National Medical ◽  
Oncological Care

Organizational aspects of specialized including high-tech oncological medical care in a multi-field hospital are shown. A 10-year experience of the Pirogov National Medical and Surgical Center regarding optimization of the treatment of cancer patients is reported. Effectiveness of oncological care organization in a multi-field hospital is preliminary concluded. It is emphasized that multidisciplinary approach is essential for selecting a personalized program of cancer treatment in these patients. The need for further searching for ways to improve the diagnosis and treatment of cancer patients by accumulating and analyzing large clinical material is marked.

scholarly journals Cardiotoxicity and cardiovascular disease risk assessment for patients receiving breast cancer treatment

2017 ◽  
Vol 3 (1) ◽  
Author(s):  
Robyn A. Clark ◽  
Tania S. Marin ◽  
Narelle M. Berry ◽  
John J. Atherton ◽  
Jonathon W. Foote ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cardiovascular Disease ◽  
Risk Assessment ◽  
Cancer Treatment ◽  
Disease Risk ◽  
Cardiovascular Disease Risk ◽  
Breast Cancer Treatment

Pressure ulcers – risk assessment, diagnosis and treatment

Leczenie Ran ◽  
2019 ◽  
Vol 16 (3-4) ◽  
pp. 74-78
Author(s):  
Izabela Kuberka ◽  
Joanna Głowacz ◽  
Marta Bakowska
Keyword(s):  
Risk Assessment ◽  
Pressure Ulcers ◽  
Diagnosis And Treatment

Polydopamine may be easily functionalized with a range of nanomaterials for synergistic cancer therapy, in addition to its exceptional photothermal effects

2021 ◽  
Author(s):  
Moataz Dowaidar
Keyword(s):  
Magnetic Resonance ◽  
Cancer Therapy ◽  
Cancer Treatment ◽  
Large Scale ◽  
Diagnosis And Treatment ◽  
Self Healing ◽  
Adhesive Properties ◽  
Uniform Size ◽  
Photothermal Treatment ◽  
Photothermal Effects

This review carefully reviewed recent polydopamine (PDA) research, including targeted therapy and cancer synergistic medications. Recent breakthroughs in photothermal treatment coupled with complex therapies such as gene therapy, radiation, and especially immunotherapy were highlighted. Due to their exceptional biocompatibility, degradability, low toxicity and high photothermal conversion efficiency, facile oxidative self-polymerization of dopamine can create PDA and serve as an excellent nanocarrier or photothermal cancer treatment agent. Due to its high adhesive capacity, PDA may be easily functionalized with a range of nanomaterials for synergistic cancer therapy, in addition to its exceptional photothermal effects. Although PDA-based multifunctional nanoplatforms have gained interest for synergistic cancer therapy, such as chemo-photothermal treatment and photodynamic-photothermal treatment, discovering novel uses for PDA remains tough. First, despite its easy and mild process of synthesis, large-scale synthesis with uniform size and thickness is challenging owing to the absence of consistent quality control standards. Second, due to the strong adhesive properties of PDA, multifunctional nanoplatforms are prone to aggregating in a solution. Third, to improve PDA's clinical application, its safety should be fully researched. Before being deployed in clinical settings, PDA-based multifunctional systems need additional research. A PDA-based multifunctional platform for better synergistic cancer treatment is a forward-looking strategy. In particular, PDA-based immunotherapy systems will remain a research center.Besides immunotherapy, in recent years, the integration of cancer diagnosis and treatment has gained a lot of publicity. Polyphenols have been proven to suppress tumor development and interact with metals such as Fe3+, Pt4+, Cu2+, etc (MPNs). MPNs are biocompatible, functional, pH-responsive and can escape endosomes. PDA has the potential to develop MPNs with contrasting magnetic resonance agents like gadolinium due to the enormous quantity of catechol groups on its surface, allowing magnetic resonance imaging. Polyphenols also have tumor-inhibiting effects, and PDA's photothermal activity can ablate tumors. Consequently, PDA-based MPNs might be a promising way to integrate diagnosis and treatment. Moreover, polydopamine can crosslink acrylamide and other polymers to form anticancer and antibacterial hydrogels. Increasing the stickiness of polydopamine hydrogels is now underway, paving the path for self-adhesive bioelectronics hydrogels. Bioelectron self-adhesion and other capabilities such as self-healing, transparency, and bacterio-toxicity may be supplied to polydopamine hydrogels by altering phenolquinone's redox process. A prospective future trend is using self-adhesive polydopamine hydrogels with current bioelectronic materials. We think that polydopamine hydrogels will eventually advance from skin patches to implantable integrated bioelectronics.

scholarly journals Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline

2016 ◽  
Vol 101 (2) ◽  
pp. 364-389 ◽  
Author(s):  
Stefan R. Bornstein ◽  
Bruno Allolio ◽  
Wiebke Arlt ◽  
Andreas Barthel ◽  
Andrew Don-Wauchope ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Adrenal Insufficiency ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Diagnosis And Treatment ◽  
Primary Adrenal Insufficiency ◽  
Endocrine Society

Anxiety among immunotherapy patients: Preliminary findings from Immunotherapy & Me.

2020 ◽  
Vol 38 (5_suppl) ◽  
pp. 104-104
Author(s):  
Alyssa Marie Jaisle ◽  
Nicholas James Power ◽  
Linda S. House ◽  
Tameka N. Jones ◽  
Lee S. Schwartzberg
Keyword(s):  
Cancer Treatment ◽  
Cancer Patients ◽  
Age Groups ◽  
Diagnosis And Treatment ◽  
Distress Screening ◽  
Physically Active ◽  
Cancer Support ◽  
Support Resources ◽  
World Class ◽  
And Gender

104 Background: Immunotherapy is a relatively new method of cancer treatment which has seen little research into its psychosocial side effects. A clearer understanding of the source of anxiety for those undergoing immunotherapy is crucial as anxiety during cancer treatment can result in decreased treatment adherence, increased mortality rates, and other negative outcomes. This study surveyed 112 cancer patients undergoing immunotherapy to understand their top treatment-related concerns. Methods: RNs in twelve clinics across the U.S. recruited participants into Immunotherapy & Me, a study run by the Cancer Support Community (CSC). Participants were given access to a selection of CSC’s world-class support resources designed to help them and their loved ones manage their treatment. While accessing these resources, participants were encouraged to complete a monthly survey online either at their clinic or at home for seven months. This survey included CancerSupportSource – CSC’s scientifically-validated distress screening tool – as well as some additional questions specifically tailored to immunotherapy patients. Results: The most frequent source of concern related to diagnosis and treatment was “feeling too tired to do things you want to need or do” ( M = 1.21, SD = 1.01), closely followed by “exercising and being physically active” ( M = 1.05, SD = .93). Other concerns included the future ( M = 1.03, SD = .99) and financial ( M = 1.02, SD = 1.16). There were significant differences between age groups in concerns about disruption to life F(4, 97) = 3.52, p < .01; pain F(4,97) = p < .05; finances F(4,97) = 2.86, p < .05; and fatigue F(4, 96) = 2.47, p< .05. Older participants were significantly less concerned about disruption to life as compared to younger participants while younger participants were more concerned about pain than older participants. Conclusions: Cancer patients undergoing immunotherapy do not have a single, outstanding concern. Instead, these patients have several concerns, the level of which varies significantly between age groups and gender. This suggests the need for a subsequent study that explores a more refined list of categories and probes which specific aspects of diagnosis and treatment generate these concerns. Clinical trial information: NCT03347058.

Sign in / Sign up

Export Citation Format

Share Document